https://www.spreaker.com/podcast/immune-checkpoint-inhibitors-on-advanced--2104585enSociety & CultureCopyright AlanWoodshttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/597df7a2fd2ac3e7bbab34d7b96a1d19.jpghttps://www.spreaker.com/podcast/immune-checkpoint-inhibitors-on-advanced--2104585Sat, 08 Apr 2023 04:39:17 +0000AlanWoodsAlanWoodsfeeds@spreaker.comcleanepisodichttps://www.spreaker.com/episode/immune-checkpoint-inhibitors-on-advanced-nsclc--10205845http://www.bocsci.com/tag/cancer-immunotherapy-36.html) on Advanced NSCLC. With the recognition of immunotherapies, there are more and more progress and breakthroughs, which also boost the development of general inhibitor products like purmorphamine (http://www.bocsci.com/purmorphamine-cas-483367-10-8-item-211514.html) and favipiravir (http://www.bocsci.com/t-705-cas-259793-96-9-item-84-463609.html).]]>https://api.spreaker.com/episode/10205845Fri, 30 Dec 2016 02:31:25 +0000AlanWoodsThis podcast is about the applications of immune checkpoint inhibitors (http://www.bocsci.com/tag/cancer-immunotherapy-36.html) on Advanced NSCLC. With the recognition of immunotherapies, there are more and more progress and breakthroughs, which also...http://www.bocsci.com/tag/cancer-immunotherapy-36.html) on Advanced NSCLC. With the recognition of immunotherapies, there are more and more progress and breakthroughs, which also boost the development of general inhibitor products like purmorphamine (http://www.bocsci.com/purmorphamine-cas-483367-10-8-item-211514.html) and favipiravir (http://www.bocsci.com/t-705-cas-259793-96-9-item-84-463609.html).]]>344immune checkpoint inhibitors,nsclccleanfull